Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HolleyPharm Patent Infringement Lawsuit Takes Favorable Turn

This article was originally published in PharmAsia News

Executive Summary

The Patent Re-examination Board of the State Intellectual Property Office of the P.R.C. has given its verdict on the copyright infringement case of Holley Pharmaceuticals (Chongqing) against Chongqing Jianqiao Pharmaceutical Development's product (PharmAsia News, July 28, 2008). SIPO decided that Chongqing Jianqiao's dihydroartemisinin patent lacks creative innovation, thus has ruled in favor of HolleyPharm's subsidiary Beijing Holly-Cotec Pharmaceuticals application for declaring the patent invalid. The judgment will serve as evidence for HolleyPharm's copyright lawsuit appeal to Chongqing Higher People's Court. (Click here for more - Chinese Language)

You may also be interested in...



Holley Pharmaceuticals Loses Copyright Infringement Case

Chongqing Intermediate People's Court has declared Holley Pharmaceuticals (Chongqing) guilty of infringing on Chongqing Jianqiao Pharmaceutical Development's copyright. It ordered HolleyPharm to stop production of its Duo-Cotecxin (dihydroartemisinin) tablets immediately and destroy any drugs produced before the ruling, as well as pay Chongqing Jianqiao 1 yuan for economic losses. HolleyPharm has indicated it will appeal to Chongqing Higher People's Court but states that there will be little impact on its overseas drug production and sales even if the future ruling remains the same. According to the company, Duo-Cotecxin revenue in China makes up only 1 percent of its total income. (Click here for more - Chinese Language)

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.

UsernamePublicRestriction

Register

OM011382

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel